Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex testing products for the In-Vitro diagnostics market.
No risks detected for 6598 from our risk checks.
Applied BioCode Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$36.40|
|52 Week High||NT$36.10|
|52 Week Low||NT$125.00|
|1 Month Change||-1.22%|
|3 Month Change||-23.04%|
|1 Year Change||-70.04%|
|3 Year Change||-13.54%|
|5 Year Change||n/a|
|Change since IPO||-47.63%|
Recent News & Updates
We're Interested To See How Applied BioCode (TPE:6598) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Introducing Applied BioCode (TPE:6598), A Stock That Climbed 11% In The Last Three Years
The last three months have been tough on Applied BioCode Corporation ( TPE:6598 ) shareholders, who have seen the share...
|6598||TW Medical Equipment||TW Market|
Return vs Industry: 6598 underperformed the TW Medical Equipment industry which returned 4.6% over the past year.
Return vs Market: 6598 underperformed the TW Market which returned 33.6% over the past year.
Stable Share Price: 6598 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 6598's weekly volatility (4%) has been stable over the past year.
About the Company
Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex testing products for the In-Vitro diagnostics market. The company’s products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the PCR amplification, hybridization, and detection steps of molecular testing; and the BioCode 2500 analyzer, a system that reads barcoded magnetic beads (BMB) and displays the barcode and fluorescence intensity for each BMB. It also develops assays, such as BioCode gastrointestinal (GI) pathogen panels for common GI pathogens, including viruses, bacteria, and parasites that cause infectious diarrhea; and BioCode sexually transmitted infections (STI) panels for detection of common infectious agents causing STDs, as well as MDx assays pipeline for various molecular tests.
Applied BioCode Fundamentals Summary
|6598 fundamental statistics|
Is 6598 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6598 income statement (TTM)|
|Cost of Revenue||NT$140.30m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.66|
|Net Profit Margin||-13.98%|
How did 6598 perform over the long term?See historical performance and comparison
Is Applied BioCode undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6598's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 6598's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 6598 is unprofitable, so we can't compare its PE Ratio to the TW Medical Equipment industry average.
PE vs Market: 6598 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6598's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6598 is overvalued based on its PB Ratio (3x) compared to the TW Medical Equipment industry average (2.1x).
How is Applied BioCode forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Applied BioCode has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Applied BioCode performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6598 is currently unprofitable.
Growing Profit Margin: 6598 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6598 is unprofitable, but has reduced losses over the past 5 years at a rate of 16.6% per year.
Accelerating Growth: Unable to compare 6598's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6598 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (9.5%).
Return on Equity
High ROE: 6598 has a negative Return on Equity (-5.47%), as it is currently unprofitable.
How is Applied BioCode's financial position?
Financial Position Analysis
Short Term Liabilities: 6598's short term assets (NT$925.9M) exceed its short term liabilities (NT$72.6M).
Long Term Liabilities: 6598's short term assets (NT$925.9M) exceed its long term liabilities (NT$54.0M).
Debt to Equity History and Analysis
Debt Level: 6598 is debt free.
Reducing Debt: 6598 had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6598 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6598 has sufficient cash runway for 3 years if free cash flow continues to grow at historical rates of 7% each year.
What is Applied BioCode current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6598's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6598's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6598's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6598's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 6598's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Winston Z. Ho, Ph.D. is Founder of Applied BioCode Corporation and serves as its President, Chief Technology Officer. Dr. Ho is the Founder of Applied BioCode, Inc. and serves as its President. Dr. Ho...
Experienced Board: 6598's board of directors are considered experienced (5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Applied BioCode Corporation's employee growth, exchange listings and data sources
- Name: Applied BioCode Corporation
- Ticker: 6598
- Exchange: TWSE
- Founded: 2016
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: NT$2.974b
- Shares outstanding: 81.70m
- Website: https://www.apbiocode.com
- Applied BioCode Corporation
- 10020 Pioneer Boulevard
- Suite 102
- Santa Fe Springs
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/20 08:33|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.